Myelofibrosis
- Treat symptoms/spleen burden + disease risk
- JAK inhibitor is the main drug class for symptomatic disease
- Choice depends on anemia, platelets + prior therapy
- Transfusions/anemia-directed therapy may be needed
- Allogeneic transplant is the only curative therapy
- Monitor progression to acute leukemia
Use at a glance
- Treat symptoms/spleen burden + disease risk
Escalation / refractory disease
- JAK inhibitor is the main drug class for symptomatic disease
- Transfusions/anemia-directed therapy may be needed
- Allogeneic transplant is the only curative therapy
Choosing treatment
- Choice depends on anemia, platelets + prior therapy
Monitoring / follow-up
- Monitor progression to acute leukemia
Self-check
- What is the main drug class for symptomatic myelofibrosis?
A JAK inhibitor. - Which progression is monitored in myelofibrosis?
Progression to acute leukemia.
Drugs used for this (1)
All clinical uses · Open Myelofibrosis in the interactive console ↗